JP2024521679A5 - - Google Patents

Info

Publication number
JP2024521679A5
JP2024521679A5 JP2023571569A JP2023571569A JP2024521679A5 JP 2024521679 A5 JP2024521679 A5 JP 2024521679A5 JP 2023571569 A JP2023571569 A JP 2023571569A JP 2023571569 A JP2023571569 A JP 2023571569A JP 2024521679 A5 JP2024521679 A5 JP 2024521679A5
Authority
JP
Japan
Prior art keywords
cells
nucleic acid
gsh
promoter
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023571569A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024521679A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/030024 external-priority patent/WO2022246063A1/en
Publication of JP2024521679A publication Critical patent/JP2024521679A/ja
Publication of JP2024521679A5 publication Critical patent/JP2024521679A5/ja
Pending legal-status Critical Current

Links

JP2023571569A 2021-05-20 2022-05-19 ゲノムセーフハーバー Pending JP2024521679A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163190996P 2021-05-20 2021-05-20
US63/190,996 2021-05-20
PCT/US2022/030024 WO2022246063A1 (en) 2021-05-20 2022-05-19 Genomic safe harbors

Publications (2)

Publication Number Publication Date
JP2024521679A JP2024521679A (ja) 2024-06-04
JP2024521679A5 true JP2024521679A5 (https=) 2025-05-26

Family

ID=84141733

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023571569A Pending JP2024521679A (ja) 2021-05-20 2022-05-19 ゲノムセーフハーバー

Country Status (7)

Country Link
US (1) US20250087304A1 (https=)
EP (1) EP4352519A4 (https=)
JP (1) JP2024521679A (https=)
KR (1) KR20240023030A (https=)
AU (1) AU2022277688A1 (https=)
CA (1) CA3219160A1 (https=)
WO (1) WO2022246063A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025049807A1 (en) * 2023-08-31 2025-03-06 Ryne Biotechnology Inc. Methods and compositions for engineered da neuronal cells
CN118256559B (zh) * 2024-01-24 2024-09-17 中国医学科学院阜外医院 制备射血分数保留的心衰的动物模型的方法
WO2026064739A1 (en) * 2024-09-23 2026-03-26 Carbon Biosciences, Inc. Parvovirus compositions and related methods for gene therapy

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011104382A1 (en) * 2010-02-26 2011-09-01 Cellectis Use of endonucleases for inserting transgenes into safe harbor loci
CN110891420B (zh) * 2017-07-31 2022-06-03 瑞泽恩制药公司 Cas转基因小鼠胚胎干细胞和小鼠及其应用
CA3084185A1 (en) * 2017-12-06 2019-06-13 Generation Bio Co. Gene editing using a modified closed-ended dna (cedna)
MA52116A (fr) * 2018-03-02 2021-01-06 Generation Bio Co Vecteurs d'adn à extrémité fermée (cedna) pour l'insertion de transgènes au niveau de havres génomiques sécuritaires (gsh) dans des génomes humains et murins
EP3759226A4 (en) * 2018-03-02 2022-06-15 Generation Bio Co. IDENTIFICATION AND CHARACTERIZATION OF GENOMIC SAFE HARBOR (GSH) IN HUMAN AND MURINE GENOMES AND VIRAL AND NON-VIRAL VECTOR COMPOSITIONS FOR TARGETED INTEGRATION AT IDENTIFIED GSH LOCI
US20200370067A1 (en) * 2019-05-21 2020-11-26 University Of Washington Method to identify and validate genomic safe harbor sites for targeted genome engineering
WO2021055592A1 (en) * 2019-09-17 2021-03-25 Memorial Sloan-Kettering Cancer Center Methods for identifying genomic safe harbors
EP4032092A4 (en) * 2019-09-17 2023-12-06 Memorial Sloan Kettering Cancer Center Genomic safe harbors for transgene integration
EP4034640A4 (en) * 2019-09-23 2023-10-25 Regents Of The University Of Minnesota GENETICALLY EDITED IMMUNE CELLS AND THERAPY METHODS
EP4045539A4 (en) * 2019-10-17 2024-03-13 Fate Therapeutics, Inc. Enhanced chimeric antigen receptor for immune effector cell engineering and use thereof

Similar Documents

Publication Publication Date Title
US11766487B2 (en) Treatments for retinal disease
JP7704998B2 (ja) 組換えウイルスベクター及びそれの産生のための核酸
JP2024521679A5 (https=)
WO2023284879A1 (en) Modified aav capsid for gene therapy and methods thereof
US12453783B2 (en) Nucleic acid molecules containing spacers and methods of use thereof
EP4227415A2 (en) Capsid-free aav vectors, compositions, and methods for vector production and gene delivery
Arbabi et al. Gene therapy for inherited retinal degeneration
US20220177529A1 (en) Fusion protein for enhancing gene editing and use thereof
US20220290181A1 (en) Codon optimized rpgrorf15 genes and uses thereof
CN117881696A (zh) 具有反向末端重复序列的封闭末端dna产生
CN111718420A (zh) 一种用于基因治疗的融合蛋白及其应用
JP2025515030A5 (https=)
US20260035726A1 (en) Recombinant polyadenylation signal sequences and use thereof
US20250188490A1 (en) Methods of raav packaging
US20250320524A1 (en) Effectively packaging high-quality raav vectors by minicircle dual transfection
HK40128602A (zh) 改进的重组多腺苷酸化信号序列及其用途
HK40100824A (zh) 密码子优化的rpgrorf15基因及其用途
EA049295B1 (ru) Рекомбинантные вирусные векторы и нуклеиновые кислоты для их получения
Patel Process Design for Scalable Recombinant Adeno-Associated Virus